HER-096 was selected based on clear and compelling preclinical data including that it:
- Effectively penetrates the Blood-Brain-Barrier (BBB)
- Potently protects neurons and restores their functional phenotype
- Significantly reduces aggregation of the toxic protein alpha-synuclein and the associated neuroinflammation
- Restores proteostasis
In 2018, Herantis began conducting lead optimization of several xCDNF molecular candidates to maximize their plasma half-life, BBB penetrance and potency for targeting PD. Neurodegenerative disorders such as PD are characterised by increased levels of cellular stress and the breakdown of proteostasis, which is the normal mechanism that directs the synthesis and folding of proteins, and also the removal of misfolded proteins. HER-096 has the potential to be a disease-modifying therapy, designed to be given via subcutaneous injection with no requirement for surgery.
As a result the Herantis pipeline now comprises two promising Parkinsons assets: CDNF (Cerebral Dopamine Neurotrophic Factor), a clinical stage biological, and HER-096 a preclinical stage compound. The two assets will continue to be developed as separate projects in tandem.
"Our nomination of HER-096 as the preclinical candidate is a key milestone as there are very few brain-penetrating compounds with disease-modifying potential out there. This has been an important R&D program for Herantis as it not only has strengthened our pipeline but also has improved our understanding of the mechanistic basis of CDNF action, generating important synergies between the two programs," Dr.
"It is exciting to have achieved this diligent milestone, and move forward with our xCDNF nominated candidate for the treatment of PD and other neurodegenerative disorders. This decision reflects our primary goal to bring a well-tolerated and effective disease-modifying treatment to patients," said Dr.
About CDNF & HER-096
CDNF is a powerful protein that occurs naturally in the body whose normal role is to protect neurons via its ability to protect and restore a key biological system/process called Proteostasis, which becomes dysfunctional in PD. Herantis is looking to harness this natural potential as a potent treatment for illnesses like Parkinson's Disease. CDNF acts upon three key elements of proteostasis: synthesis, folding, and degradation, and can thereby reduce cellular stress and prevent formation of protein aggregates. However, CDNF cannot readily penetrate an intact blood-brain-barrier (BBB). HER-096 is a synthetic peptidomimetic version of CDNF, designed to be given via subcutaneous injection with no requirement for surgery. xCDNF has been engineered with the dual aims of crossing the notoriously impermeable BBB, while retaining the potency of the parent molecule to protect neurons, both critical elements for successful Parkinsons treatment.
Target Market
Comprehensively, the total available market for neurodegenerative diseases was estimated to be worth E29.2Bn in 2018 and is projected to reach E54Bn by 2026 (CAGR = 7.2%). PD represents a serviceable market of E3.8Bn, growing to E5.0Bn by 2024. PD is the second most common form of neurodegeneration, affecting 7 to 10 million people worldwide, with over 60,000 new diagnoses in the US each year. Based on the market shares of incumbent therapeutics for PD, the overall market opportunity for Herantis CDNF assets is independently estimated to be approximately E8Bn.
For more information, please contact:
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
Certified Advisor:
Company website: www.herantis.com
About
Herantis focuses on disease modifying therapies for debilitating neurodegenerative diseases by restoring the neuronal protective mechanism of proteostasis, a key system in neurodegenerative disease. Proteostasis regulates proteins within the body and influences the fate of every protein from synthesis to degradation. Its failure results in a vicious cycle of pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated with the development of many neurodegenerative diseases including Parkinson's Disease, Alzheimer's and other diseases. CDNF is a protein that occurs naturally in the body whose normal role is to protect neurons by balancing and supporting proteostasis, thereby preventing and counteracting disease generating mechanisms. Herantis is taking this natural ability and harnessing it as a treatment for neurodegenerative disease. CDNF - a biological protein - is Herantis' lead program and a clinical stage asset; and HER-096 - a synthetic peptidomimetic version of CDNF - is Herantis' follow-on program. Both CDNF and HER-096 have, via their multimodal mechanism of action, the potential to improve neuronal survival and function, and to stop the progression of Parkinson's and other neurodegenerative disease and have a significant therapeutic impact on the lives of patients.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit https://www.herantis.com
https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-announces-xcdnf-preclinical-candidate-selection,c3357217
https://mb.cision.com/Main/18884/3357217/1425102.pdf
(c) 2021 Cision. All rights reserved., source